Friday witnessed an extraordinary surge in the cannabis sector, with Tilray Brands, Inc. shares leading the charge. The stock skyrocketed by over 44% in a single session, marking one of the most dramatic moves the industry has seen in recent years. This explosive activity was triggered by a report from the Washington Post indicating the Trump administration is preparing to reclassify marijuana from a Schedule I to a Schedule III controlled substance.
Sector-Wide Euphoria and Unprecedented Volume
The rally was not confined to Tilray. The entire cannabis space experienced a powerful uplift, a phenomenon some traders are calling the “Trump Put.” Competitors like Canopy Growth and major cannabis-focused ETFs posted double-digit gains. However, Tilray, acting as a sector bellwether due to its high liquidity, attracted the most capital. Trading volume for the company exploded to more than 80 million shares, a staggering increase from its average of around 5 million. Speculation is now mounting that an executive order on reclassification could be signed as early as Monday.
The Fundamental Impact of Schedule III
The potential regulatory shift represents a game-changing development for cannabis companies. Moving to Schedule III would eliminate the crippling Section 280E of the U.S. tax code, which currently prohibits businesses dealing in Schedule I substances from deducting standard operating expenses. For Tilray, the implications are profound:
- Substantially improved cash flows due to deductible business costs
- Higher net profitability without requiring additional revenue growth
- Removal of federal regulatory stigma that has long hampered the industry
Politically, the signal would be immense, moving cannabis from the same category as heroin to one closer to prescription medications. Market participants view this as a fundamental re-rating event for the entire sector.
Should investors sell immediately? Or is it worth buying Tilray?
Erasing the Memory of Recent Consolidation
The timing of this surge is particularly notable. It comes just weeks after Tilray executed a 1-for-10 reverse stock split. Such consolidations are typically viewed with skepticism by the market, often signaling efforts to maintain exchange listing requirements. Tilray’s move was aimed at ensuring compliance and attracting institutional investment. The negative sentiment that frequently follows a reverse split has been completely overturned by the recent news. The new price level has attracted a different investor base, and extreme short-term volatility is expected to continue.
Caution Amidst the Optimism
Despite the palpable euphoria, significant uncertainty remains. The current market movement is based on media reports, not finalized legislation or an enacted order. The process for the Drug Enforcement Administration (DEA) to officially implement any change is still pending, and the exact timing and final details are unclear. The regulatory landscape, therefore, remains in flux.
Nevertheless, the market has delivered a clear verdict. The risk-reward calculus for Tilray and its peers has undergone a fundamental shift. The stock is now trading on the anticipation of a historic regulatory pivot—one that could redefine the future of the cannabis industry in the United States. All eyes are now on Washington for the next development.
Ad
Tilray Stock: Buy or Sell?! New Tilray Analysis from January 29 delivers the answer:
The latest Tilray figures speak for themselves: Urgent action needed for Tilray investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from January 29.
Tilray: Buy or sell? Read more here...
